BioCentury
ARTICLE | Clinical News

Keytruda pembrolizumab regulatory update

November 16, 2015 8:00 AM UTC

FDA granted breakthrough therapy designation to Merck’s Keytruda pembrolizumab to treat patients with metastatic colorectal cancer with high levels of microsatellite instability. The pharma is evaluating the humanized IgG4 mAb against PD-1 based on microsatellite instability status in the pivotal Phase II KEYNOTE-164 trial. ...